US equities
|
MU
$878.84
▼-5.63%
NVDA
$214.13
▼-1.43%
TSLA
$354.72
▼-2.13%
AAPL
$343.46
▲+0.43%
META
$709.33
▼-3.72%
MSFT
$529.05
▼-1.93%
SPCX
$146.03
▼-1.74%
AMD
$528.75
▼-5.95%
MU
$878.84
▼-5.63%
NVDA
$214.13
▼-1.43%
TSLA
$354.72
▼-2.13%
AAPL
$343.46
▲+0.43%
META
$709.33
▼-3.72%
MSFT
$529.05
▼-1.93%
SPCX
$146.03
▼-1.74%
AMD
$528.75
▼-5.95%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Viatris Inc. - Common Stock
(NQ:
VTRS
)
18.66
+0.44 (+2.39%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Viatris Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
22
23
Next >
Exploring the top movers within the S&P500 index during today's session.
↗
October 14, 2026
Via
Chartmill
Why Pacira BioSciences Skyrocketed Today
↗
October 08, 2026
The specialty pharmaceutical company is being acquired.
Via
The Motley Fool
These S&P500 stocks that are showing activity before the opening bell on Thursday.
↗
October 08, 2026
Via
Chartmill
Stay informed with the top movers within the S&P500 index on Monday.
↗
September 28, 2026
Via
Chartmill
Viatris (NASDAQ:VTRS) Shares Rise as Q1 Earnings Top Estimates
↗
May 07, 2026
Via
Chartmill
3 Healthcare Stocks That Fall Short
September 14, 2026
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme...
Via
StockStory
3 Cash-Producing Stocks That Concern Us
August 31, 2026
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...
Via
StockStory
3 S&P 500 Stocks We Keep Off Our Radar
August 19, 2026
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...
Via
StockStory
Topics
Fraud
Stocks
3 Stocks Under $50 We’re Skeptical Of
August 18, 2026
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However...
Via
StockStory
Viatris (VTRS) Q2 2026 Earnings Call Transcript
↗
August 13, 2026
Greater China surges 16% as management raises full-year guidance.
Via
The Motley Fool
Topics
Earnings
5 Must-Read Analyst Questions From Viatris’s Q2 Earnings Call
August 13, 2026
Viatris’ second-quarter results were met with a negative market reaction, despite the company surpassing Wall Street’s revenue and non-GAAP profit expectatio...
Via
StockStory
Topics
Earnings
Economy
VTRS Q2 Deep Dive: China Growth, Pipeline Progress, and Margin Concerns Shape Outlook
August 07, 2026
Medication company Viatris (NASDAQ:VTRS) announced better-than-expected revenue in Q2 CY2026, with sales up 4.9% year on year to $3.76 billion. The company e...
Via
StockStory
Topics
Economy
Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q2 CY2026
August 06, 2026
Medication company Viatris (NASDAQ:VTRS) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 4.9% year on year to $3.76 billion....
Via
StockStory
Viatris (VTRS) Q2 Earnings Report Preview: What To Look For
August 04, 2026
Medication company Viatris (NASDAQ:VTRS) will be reporting earnings this Thursday before the bell. Here’s what to look for. Viatris beat analysts’ revenue ex...
Via
StockStory
Topics
Artificial Intelligence
Generic Pharmaceuticals Stocks Q1 Highlights: Viatris (NASDAQ:VTRS)
July 26, 2026
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how generic pharmaceutical...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
3 Healthcare Stocks We Keep Off Our Radar
July 24, 2026
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have...
Via
StockStory
3 Unpopular Stocks We’re Skeptical Of
July 20, 2026
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...
Via
StockStory
1 Cash-Producing Stock with Exciting Potential and 2 Facing Headwinds
June 16, 2026
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc...
Via
StockStory
1 Unpopular Stock That Should Get More Attention and 2 We Find Risky
May 22, 2026
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...
Via
StockStory
Viatris (VTRS): Buy, Sell, or Hold Post Q1 Earnings?
May 20, 2026
Viatris has been on fire lately. In the past six months alone, the company’s stock price has rocketed 58.2%, reaching $16.13 per share. This was partly thank...
Via
StockStory
This Income Fund Just Completely Exited Its $37 Million Stake in Algonquin Power. Why?
↗
May 18, 2026
Algonquin serves approximately 1.3 million customer connections across the United States, Canada, Bermuda, and Chile through its regulated utility network.
Via
The Motley Fool
Topics
Regulatory Compliance
1 Stock Under $50 to Target This Week and 2 We Avoid
May 15, 2026
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk tha...
Via
StockStory
5 Revealing Analyst Questions From Viatris’s Q1 Earnings Call
May 14, 2026
Viatris delivered a positive first quarter, outperforming Wall Street’s expectations on both revenue and non-GAAP earnings per share. Management attributed t...
Via
StockStory
Topics
Earnings
3 Unprofitable Stocks That Fall Short
May 11, 2026
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th...
Via
StockStory
VTRS Q1 Deep Dive: China Strength, R&D Pipeline, and Execution Drive Outperformance
May 08, 2026
Medication company Viatris (NASDAQ:VTRS) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 8.1% year on year to $3.52 bill...
Via
StockStory
Viatris (VTRS) Q1 2026 Earnings Transcript
↗
May 07, 2026
Viatris (VTRS) Q1 2026 Earnings Transcript
Via
The Motley Fool
These S&P500 stocks have an unusual volume in today's session
↗
May 07, 2026
Via
Chartmill
What's going on in today's session: S&P500 gap up and gap down stocks
↗
May 07, 2026
Via
Chartmill
Viatris’s (NASDAQ:VTRS) Q1 CY2026: Beats On Revenue
May 07, 2026
Medication company Viatris (NASDAQ:VTRS) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 8.1% year on year to $3.52 bil...
Via
StockStory
Topics
Artificial Intelligence
Earnings To Watch: Viatris (VTRS) Reports Q1 Results Tomorrow
May 05, 2026
Medication company Viatris (NASDAQ:VTRS) will be announcing earnings results this Thursday before the bell. Here’s what investors should know. Viatris beat a...
Via
StockStory
Topics
Artificial Intelligence
< Previous
1
2
3
4
5
6
7
8
9
...
22
23
Next >
